{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-108847","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.364363+00:00","generated_at":"2026-05-16T21:21:58.825213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Unicycive Q3 net loss $6.0M, cash $42.7M; plans OLC NDA resubmission by year-end 2025","bullets":["Net loss of $6.0M for Q3 2025 vs $4.1M in Q3 2024; cash $42.7M as of Sept 30, 2025, with runway into 2027.","On track to resubmit NDA for oxylanthanum carbonate (OLC) by year-end 2025 after positive FDA Type A meeting; potential PDUFA in H1 2026.","Presented OLC data at ASN Kidney Week showing 7x reduction in pill volume and 2x reduction in pill count vs current binders.","R&D expenses flat at $3.0M; G&A increased to $4.4M from $3.2M due to higher labor and consulting costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-108847","json":"https://secwatch.observer/filing/0001213900-25-108847.json","markdown":"https://secwatch.observer/filing/0001213900-25-108847.md","text":"https://secwatch.observer/filing/0001213900-25-108847.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/0001213900-25-108847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025108847/ea0265227-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:21:58.825213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}